GlaxoSmithKline (GSK) and Amicus Therapeutics have announced that Amicus has received global rights for the global drug development, regulatory and commercial activities of migalastat HCl as a monotherapy and in combination with enzyme ...
Tags: GlaxoSmithKline, Fabry Agreement